Literature DB >> 2923511

Cyclosporin for dermatomyositis.

S Levi, H J Hodgson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2923511      PMCID: PMC1003686          DOI: 10.1136/ard.48.1.85

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Severe dermatomyositis treated with cyclosporin A.

Authors:  L Ejstrup
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

3.  Cell-mediated cytotoxicity to muscle in polymyositis. Effect of immunosuppression.

Authors:  R L Dawkins; F L Mastaglia
Journal:  N Engl J Med       Date:  1973-03-01       Impact factor: 91.245

4.  Dermatomyositis without creatine kinase elevation. A poor prognostic sign.

Authors:  E J Fudman; T J Schnitzer
Journal:  Am J Med       Date:  1986-02       Impact factor: 4.965

5.  Interstitial lung disease in dermatomyositis: clinicopathological study.

Authors:  H Takizawa; J Shiga; Y Moroi; S Miyachi; M Nishiwaki; T Miyamoto
Journal:  J Rheumatol       Date:  1987-02       Impact factor: 4.666

  5 in total
  1 in total

Review 1.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.